Covaxin phase 3 data shows 77.8% efficacy: Lancet{br} https://ift.tt/eA8V8J
A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.
from Times of India https://ift.tt/30aDSMa
from Times of India https://ift.tt/30aDSMa
Comments
Post a Comment